Cuardaigh le haghaidh roghanna malartacha:
harm » farm (Leathnaigh an cuardach)
removed. » resolved. (Leathnaigh an cuardach)
resolve. » resolved. (Leathnaigh an cuardach)
61 - 80 toradh á dtaispeáint as 231 toradh san iomlán ar an gcuardach 'harm is (((((removed. OR removesdssds.) OR involves.) OR remove.) OR involved.) OR resolve.)', am iarratais: 0.14s Beachtaigh na torthaí
  1. 61
    Show the BET N2 adsorption/desorption isotherm for calculating the surface area of Fe<sub>3</sub>O<sub>4</sub> (a), and the XRD pattern of Fe<sub>3</sub>O<sub>4</sub> (b).

    Show the BET N2 adsorption/desorption isotherm for calculating the surface area of Fe<sub>3</sub>O<sub>4</sub> (a), and the XRD pattern of Fe<sub>3</sub>O<sub>4</sub> (b). de réir Tamer S. Saleh (5181146)

    Foilsithe / Cruthaithe 2025
    Ábhair:
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 62
    Development of immune factors over visits in the AAF and AAF-syn treatment group as (A) scores and (B) loadings.

    Development of immune factors over visits in the AAF and AAF-syn treatment group as (A) scores and (B) loadings. de réir Diana M. Hendrickx (1507435)

    Foilsithe / Cruthaithe 2025
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 63
    Results of comparing visits within allergy groups using linear mixed models and post hoc analysis.

    Results of comparing visits within allergy groups using linear mixed models and post hoc analysis. de réir Diana M. Hendrickx (1507435)

    Foilsithe / Cruthaithe 2025
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 64
    Results of comparing allergy groups within visits using linear mixed models and post hoc analysis.

    Results of comparing allergy groups within visits using linear mixed models and post hoc analysis. de réir Diana M. Hendrickx (1507435)

    Foilsithe / Cruthaithe 2025
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 65
    Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference.

    Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference. de réir Diana M. Hendrickx (1507435)

    Foilsithe / Cruthaithe 2025
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 66
    Results of comparing treatment groups within visits using linear mixed models and post hoc analysis.

    Results of comparing treatment groups within visits using linear mixed models and post hoc analysis. de réir Diana M. Hendrickx (1507435)

    Foilsithe / Cruthaithe 2025
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 67
    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis.

    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis. de réir Diana M. Hendrickx (1507435)

    Foilsithe / Cruthaithe 2025
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 68
    Results of comparing visits within treatment groups using linear mixed models and post hoc analysis.

    Results of comparing visits within treatment groups using linear mixed models and post hoc analysis. de réir Diana M. Hendrickx (1507435)

    Foilsithe / Cruthaithe 2025
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 69
    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis.

    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis. de réir Diana M. Hendrickx (1507435)

    Foilsithe / Cruthaithe 2025
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 70
    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determined with ConsensusPathDB.

    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determ... de réir Diana M. Hendrickx (1507435)

    Foilsithe / Cruthaithe 2025
    Cuir le mo chuid Ceanán
    Sábháilte in:
  11. 71
    Results of comparing treatment groups within visits using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing treatment groups within visits using KEGG pathway enrichment in ConsensusPathDB. de réir Diana M. Hendrickx (1507435)

    Foilsithe / Cruthaithe 2025
    Cuir le mo chuid Ceanán
    Sábháilte in:
  12. 72
    Results of comparing allergy groups within visits using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing allergy groups within visits using KEGG pathway enrichment in ConsensusPathDB. de réir Diana M. Hendrickx (1507435)

    Foilsithe / Cruthaithe 2025
    Cuir le mo chuid Ceanán
    Sábháilte in:
  13. 73
    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within treatment groups as determined with ConsensusPathDB.

    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within treatment groups as determ... de réir Diana M. Hendrickx (1507435)

    Foilsithe / Cruthaithe 2025
    Cuir le mo chuid Ceanán
    Sábháilte in:
  14. 74
    Results of comparing visits within treatment groups using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing visits within treatment groups using KEGG pathway enrichment in ConsensusPathDB. de réir Diana M. Hendrickx (1507435)

    Foilsithe / Cruthaithe 2025
    Cuir le mo chuid Ceanán
    Sábháilte in:
  15. 75
    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within allergy groups as determined with ConsensusPathDB.

    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within allergy groups as determin... de réir Diana M. Hendrickx (1507435)

    Foilsithe / Cruthaithe 2025
    Cuir le mo chuid Ceanán
    Sábháilte in:
  16. 76
    Results of comparing visits within allergy groups using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing visits within allergy groups using KEGG pathway enrichment in ConsensusPathDB. de réir Diana M. Hendrickx (1507435)

    Foilsithe / Cruthaithe 2025
    Cuir le mo chuid Ceanán
    Sábháilte in:
  17. 77
    Potential mechanisms for persistent CMA (left) and resolution of CMA (right) revealed by our study.

    Potential mechanisms for persistent CMA (left) and resolution of CMA (right) revealed by our study. de réir Diana M. Hendrickx (1507435)

    Foilsithe / Cruthaithe 2025
    Cuir le mo chuid Ceanán
    Sábháilte in:
  18. 78
    Results of the molecular docking.

    Results of the molecular docking. de réir Naisarg Patel (21772572)

    Foilsithe / Cruthaithe 2025
    Ábhair:
    Cuir le mo chuid Ceanán
    Sábháilte in:
  19. 79
    Interaction between the CFTR protein with drug molecules upon Molecular Docking.

    Interaction between the CFTR protein with drug molecules upon Molecular Docking. de réir Naisarg Patel (21772572)

    Foilsithe / Cruthaithe 2025
    Ábhair:
    Cuir le mo chuid Ceanán
    Sábháilte in:
  20. 80
    ADMET Scan Results.

    ADMET Scan Results. de réir Naisarg Patel (21772572)

    Foilsithe / Cruthaithe 2025
    Ábhair:
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: